Rodman and Renshaw senior biotech analyst Dr. Reni Benjamin discusses the causes behind the more than 60% wipeout in Dendreon's market value after their earnings report and how he is tweaking his models going forward.

Rodman and Renshaw's Benjamin on the DNDN earnings debacle

Benzinga dives into the market to uncover trends in various sectors and asset classes with top company management, fund managers, and Wall Street analysts to bring you actionable trading ideas and keep you abreast of the various undercurrents in financial markets around the world.

Share Rodman and Renshaw's Benjamin on the DNDN earnings debacle

Sign up to save your podcasts

Rodman and Renshaw's Benjamin on the DNDN earnings debacle

Rodman and Renshaw's Benjamin on the DNDN earnings debacle